Market Research Logo

Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2015

Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2015’, provides an overview of the Relapsed Chronic Lymphocytic Leukemia (CLL)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Relapsed Chronic Lymphocytic Leukemia (CLL)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Relapsed Chronic Lymphocytic Leukemia (CLL) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Relapsed Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Relapsed Chronic Lymphocytic Leukemia (CLL) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Relapsed Chronic Lymphocytic Leukemia (CLL)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Relapsed Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Relapsed Chronic Lymphocytic Leukemia (CLL) Overview
Therapeutics Development
Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Overview
Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis
Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies
Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies
Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes
Relapsed Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development
4SC AG
AbbVie Inc.
Astellas Pharma Inc.
Astex Pharmaceuticals, Inc.
AstraZeneca Plc
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corporation
Emergent BioSolutions Inc.
F. Hoffmann-La Roche Ltd.
Genmab A/S
Gilead Sciences, Inc.
GlaxoSmithKline Plc
ImmunoGen, Inc.
Immunomedics, Inc.
Infinity Pharmaceuticals, Inc.
Innate Pharma SA
Juno Therapeutics Inc.
Karyopharm Therapeutics, Inc.
Les Laboratoires Servier SAS
LFB S.A.
MedImmune, LLC
Millennium Pharmaceuticals, Inc.
MorphoSys AG
Neopharm Ltd.
Novartis AG
Ono Pharmaceutical Co., Ltd.
Portola Pharmaceuticals, Inc.
Sanofi
TG Therapeutics, Inc.
Threshold Pharmaceuticals, Inc.
Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
4SC-202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ACP-196 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
afuresertib hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AGS-67E - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AT-7519 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AZD-6738 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BI-836826 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-986016 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
buparlisib hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CC-122 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy to Target Receptor Tyrosine Kinase-Like Orphan Receptor 1 for Chronic Lymphocytic Leukemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cerdulatinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
duvelisib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
evofosfamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FBTA-05 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GS-9901 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IMGN-529 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IMMU-114 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IPH-2201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JCAR-014 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JCAR-015 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MEDI-551 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MOR-208 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
moxetumomab pasudotox - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nivolumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
obinutuzumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ofatumumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oshadi D + Oshadi R - Drug Profile
Product Description
Mechanism of Action
R&D Progress
otlertuzumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pilaralisib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-055746 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
selinexor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
spebrutinib besylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TAK-659 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TGR-1202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tisagenlecleucel-T - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ublituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ublituximab [INN] + TGR-1202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
UC-961 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ulocuplumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
urelumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
venetoclax - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Relapsed Chronic Lymphocytic Leukemia (CLL) - Recent Pipeline Updates
Relapsed Chronic Lymphocytic Leukemia (CLL) - Dormant Projects
Relapsed Chronic Lymphocytic Leukemia (CLL) - Discontinued Products
Relapsed Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones
Featured News & Press Releases
May 31, 2015: TG Therapeutics Announces Presentations of Its Proprietary Combination of TG-1101 Plus TGR-1202 in Ongoing Phase I/Ib Dose Escalation Clinical Studies
May 21, 2015: Ofatumumab Data to Be Presented at 20th Congress of EHA
May 11, 2015: Abbvie To Present New Data From Studies Of Duvelisib Assets In Multiple Cancers At The 51st American Society Of Clinical Oncology Annual Meeting
May 06, 2015: Investigational Medicine Venetoclax Receives Breakthrough Therapy Designation In Relapsed Or Refractory Chronic Lymphocytic Leukemia In Previously Treated Patients With The 17P Deletion Genetic Mutation
Dec 05, 2014: Roche to present clinical data on obinutuzumab at ASH
Nov 06, 2014: Portola Pharmaceuticals Announces Upcoming Presentations on Cerdulatinib at the American Society of Hematology 2014 Annual Meeting
Nov 06, 2014: Infinity Announces Clinical and Preclincal Data for Duvelisib to Be Presented at ASH 2014 Annual Meeting
Nov 06, 2014: Genmab Announces Additional Data from Phase III Study of Ofatumumab as Maintenance Therapy for Relapsed CLL
Nov 06, 2014: Genmab Announces Ofatumumab Data to Be Presented at American Society of Hematology Annual Meeting (ASH)
Jul 31, 2014: GSK and Genmab announce positive interim result for phase III study of ofatumumab as maintenance therapy for relapsed CLL
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL), H1 2015
Number of Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2015
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by 4SC AG, H1 2015
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc., H1 2015
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astellas Pharma Inc., H1 2015
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astex Pharmaceuticals, Inc., H1 2015
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by AstraZeneca Plc, H1 2015
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Boehringer Ingelheim GmbH, H1 2015
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bristol-Myers Squibb Company, H1 2015
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celgene Corporation, H1 2015
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Emergent BioSolutions Inc., H1 2015
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Genmab A/S, H1 2015
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Gilead Sciences, Inc., H1 2015
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by GlaxoSmithKline Plc, H1 2015
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by ImmunoGen, Inc., H1 2015
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immunomedics, Inc., H1 2015
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Infinity Pharmaceuticals, Inc., H1 2015
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innate Pharma SA, H1 2015
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Juno Therapeutics Inc., H1 2015
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Karyopharm Therapeutics, Inc., H1 2015
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Les Laboratoires Servier SAS, H1 2015
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by LFB S.A., H1 2015
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by MedImmune, LLC, H1 2015
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by MorphoSys AG, H1 2015
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Neopharm Ltd., H1 2015
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Novartis AG, H1 2015
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Portola Pharmaceuticals, Inc., H1 2015
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sanofi, H1 2015
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by TG Therapeutics, Inc., H1 2015
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics - Recent Pipeline Updates, H1 2015
Relapsed Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2015
Relapsed Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..1), H1 2015
Relapsed Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL), H1 2015
Number of Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report